GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...
In particular, it shows that a subset of people with highly inflammatory arthralgia might benefit from methotrexate, allowing inhibition of the onset of arthritis. Furthermore, molecular analyses in ...